Pretax income is the income that a company earns before paying income taxes. Chemomab Therapeutics's pretax income for the
three
months ended in Dec. 2024 was $-2.96 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-13.95 Mil.
Chemomab Therapeutics's pretax margin was %.
Chemomab Therapeutics Pre-Tax Income Historical Data
The historical data trend for Chemomab Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Chemomab Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Chemomab Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemomab Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Chemomab Therapeutics's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemomab Therapeutics (NAS:CMMB) Pre-Tax Income Explanation
Chemomab Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemomab Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Chemomab Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CMMB has been successfully added to your 